SequelSEC

AYTU BIOPHARMA, INC AYTU

Pharmaceutical Preparations · CIK 0001385818 · Fiscal year ends 0630

Revenue
$57.57M
Fiscal year ended 2026-06-30
Operating income
-$8.32M
Fiscal year ended 2026-06-30
Free cash flow
$3.25M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$7.24MMarket value of stock held by non-affiliates, as stated on the cover page for 2024-12-31
Float per share$0.73Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.4×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-12-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-06-30 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
SBC / revenue1.2%2th
R&D / revenue0.0%4th
Current ratio1.13x19th
CapEx / revenue0.1%23th
Operating margin-14.4%74th
FCF margin5.6%69th
Net margin-24.8%66th
Long-term debt / equity0.26x56th
Gross margin64.0%47th
Revenue YoY growth-13.3%48th

AYTU BIOPHARMA, INC (AYTU) reported revenue of $57.57M and net income of -$14.25M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from AYTU BIOPHARMA, INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

AYTU BIOPHARMA, INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$57.57M
Cost of revenue$20.75M
Gross profit$36.82M
Operating income-$8.32M
Net income-$14.25M
Research & development$0
Weighted-average diluted sharesUnavailable
Pretax income-$14.23M
Income tax expense$21.00K
Diluted EPSUnavailable
Selling, general & administrative$42.64M
General & administrative$19.27M
Selling & marketing$23.37M

Balance

AYTU BIOPHARMA, INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$26.31M
Total assets$105.01M
Current assets$61.76M
Total liabilitiesUnavailable
Current liabilities$54.66M
Total equity incl. NCI$35.27M
Temporary (mezzanine) equityUnavailable
Inventory$6.86M
Accounts receivable$22.78M
GoodwillUnavailable
Long-term debt$9.10M
Accounts payable$11.28M

Cash flow

AYTU BIOPHARMA, INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$3.28M
Capital expenditures$29.00K
Investing cash flow-$29.00K
Financing cash flow-$7.90M
Net change in cash-$4.64M
Stock-based compensation$691.00K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$3.93M

Derived

AYTU BIOPHARMA, INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$3.25M
Gross margin64.0%
Operating margin-14.4%
FCF margin5.6%
SBC / revenue1.2%
Current ratio1.13x
Revenue YoY growth-13.3%
Net margin-24.8%
R&D / revenue0.0%
CapEx / revenue0.1%
Long-term debt / equity0.26x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AYTU in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-09-22View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-Q · Filed 2026-02-03View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-K · Filed 2025-09-23View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.